Predictive factors for response and prognostic factors for long-term survival in consecutive, single institution patients with locally advanced and/or metastatic transitional cell carcinoma following cisplatin-based chemotherapy

Authors

  • Christian Jessen Department of Oncology, Aarhus University Hospital, Aarhus, Denmark
  • Mads Agerbaek Department of Oncology, Aarhus University Hospital, Aarhus, Denmark
  • Hans Von Der Maase Department of Oncology, Aarhus University Hospital, Aarhus, Denmark

DOI:

https://doi.org/10.1080/02841860802325932

Abstract

Purpose. The study was undertaken to identify pre-treatment clinical and histopathological factors of importance for response and survival after cisplatin-based combination chemotherapy, in patients with locally advanced or metastatic transitional cell carcinoma of the urothelium. Patients and methods. Clinical, laboratory and histopathological data from 178 consecutive patients, representing all patients treated between 1991 and 2001 in a single institution, were collected. Correlations between these data and response and survival after chemotherapy were analysed using univariate and multivariate analyses. Results. Absence of visceral metastasis was the only parameter with independent correlation to the response to chemotherapy. Two of the analysed parameters were independently associated with increased survival: good performance status (PS≤1) and absence of visceral metastases. Stratification of the patient material according to number of these risk-factors present showed strong association with survival. Conclusion. It was possible to predict survival from pre-treatment clinical parameters and consequently it is possible to select groups with a high and low probability of obtaining long term survival following cisplatin-containing chemotherapy.

Downloads

Download data is not yet available.

Downloads

Published

2009-01-01

How to Cite

Jessen, C. ., Agerbaek, M. ., & Von Der Maase, H. . (2009). Predictive factors for response and prognostic factors for long-term survival in consecutive, single institution patients with locally advanced and/or metastatic transitional cell carcinoma following cisplatin-based chemotherapy. Acta Oncologica, 48(3), 411–417. https://doi.org/10.1080/02841860802325932